Decline after immobilisation and recovery after remobilisation of synovial fluid IL1, TIMP, and chondroitin sulphate levels in young beagle dogs

J Haapala, J P A Arokoski, S Rönkkö, U Ågren, V-M Kosma, L S Lohmander, M Tammi, H J Helminen, I Kiviranta

Abstract

Objective—To monitor the concentration of markers of cartilage and synovium metabolism in the knee (stifle) joint synovial fluid of young beagles subjected to immobilisation and subsequent remobilisation.

Methods—The right hind limb of 17 dogs was immobilised in flexion for 11 weeks. Simultaneously, the contralateral left knee was exposed to increased weight bearing. The remobilisation period lasted 50 weeks. Litter mates served as controls. The concentration in joint lavage fluid of interleukin 1α (IL1α) was measured by immunoassay, the activity of phospholipase A2 (PLA2) was determined by an extraction method, chondroitin sulphate (CS) concentration by precipitation with Alcian blue, hyaluronan (HA) by an ELISA-like assay using biotinylated HA-binding complexes, matrix metalloproteinase 3 (MMP-3), and tissue inhibitor of metalloproteinases 1 (TIMP-1) by sandwich ELISA, and synovitis was scored by light microscopy.

Results—Synovitis or effusion was absent in all experimental and control groups. Immobilisation decreased the joint lavage fluid levels of IL1α (p<0.05), TIMP (p<0.05), and the concentration of CS down to 38% (p<0.05) in comparison with untreated litter mates with normal weight bearing. Immobilisation did not affect the activity of PLA2, or the concentration of MMP-3 or HA in synovial fluid. Joint remobilisation restored the decreased concentrations of markers to control levels. Increased weight bearing did not change the concentrations of markers in comparison with the control joints with normal weight bearing.

Conclusions—11 weeks’ joint immobilisation decreased the concentration of markers of cartilage and synovium metabolism in the synovial fluid, and remobilisation restored the concentrations to control levels. The changes in joint metabolism induced by immobilisation, as reflected by the markers, are thus different from those found in osteoarthritis, where increased levels of these markers are associated with enhanced degradation and synthesis. These findings suggest that the change induced in joint metabolism by immobilisation is reversible in its early stages.

Synovial fluid has a key role in diarthrodial joints by lubricating the moving cartilaginous and synovial surfaces and supplying nutrients to articular cartilage.1 The concentrations in synovial fluid of metabolic products of joint tissues are suggested to reflect tissue turnover of, and release from, the articular cartilage and other joint tissues.2 Neutral matrix metalloproteinases, like MMP-3, can cleave articular cartilage aggrecan, link protein, and collagen.2 3 Tissue inhibitor of metalloproteinases (TIMP) inhibits the activity of matrix metalloproteinases.4 5 Increased concentrations of metalloproteinases, and their tissue inhibitors have been detected in human osteoarthritis, in rheumatoid arthritis, and in early experimental osteoarthritis induced in beagles by tibial osteotomies.6 The activation of metalloproteinases can be initiated by cytokines such as interleukin 1 (IL1), whereas IL6 induces the synthesis of TIMP-1 but not of the metalloproteinases.6 7 In experimental osteoarthritis, increased concentrations of cytokines have been detected in the synovial fluid.2 8

The inflammatory component is important in the pathogenesis of articular cartilage injury.12 14 In animals, intra-articular injection of phospholipase A2 (PLA2) induces acute synovitis.14 15 The effect of PLA2 is thought to be mediated through generation of arachidonic acid, which is converted to prostaglandins, potent mediators of inflammation.16 Increased concentrations of synovial type PLA2 have been found in osteoarthritis and rheumatoid arthritis.16 17 18

Hyaluronan (HA) provides lubrication and viscoelasticity to the synovial fluid.19 Joint immobilisation reduces HA concentration in articular cartilage. This change takes place simultaneously with a decrease of aggrecan in articular cartilage, suggesting that joint loading exerts a coordinated influence on their metabolism.20 The concentration of HA in synovial fluid is reduced in osteoarthritis and rheumatoid arthritis.21

Our study aimed at monitoring changes in the synovial fluid of beagle knee joints 11 weeks after joint immobilisation and after a subsequent remobilisation period of 50 weeks. Interest was focused on changes which would allow comparison between the synovial fluid marker changes in immobilisation-induced atrophy and experimental osteoarthritis.9 The effects of increased weight bearing on the contralateral limb were also investigated. Earlier observa-
tions have suggested that the initial 11 week joint immobilisation followed by a 50 week remobilisation period causes local changes in the cartilage concentration of HA and proteoglycans, and in biomechanical properties of articular cartilage. Therefore, it seems possible that the 11 week immobilisation period may result in permanent changes in the properties of articular cartilage.

Material and methods

Animals
Thirty four female pure bred beagle dogs (Marshall Farms, North Rose, NY, USA) were used in this experiment. The dogs lived in steel cages (0.9 × 1.2 × 0.8 m) in the National Laboratory Animal Centre (Kuopio, Finland). They were fed with commercial dog food (Hankkija, Kolpi, Finland) and water. The dogs were treated in accordance with the principles presented in the National Research Council’s Guide for the Care and Use of Laboratory Animals. The Animal Care and Use Committee of the University of Kuopio approved the design of this experiment.

Immobilisation and remobilisation and increased weight bearing

The right hind limb of 17 dogs was immobilised at the age of 29 weeks for 11 weeks. The knee (stifle) joint was casted with fibreglass cast (Dynacast Pro, Smith and Nephew Medical, Hull, UK) in 90° flexion. The casted limb was tied to the trunk to avoid weight bearing by the immobilised limb. Each splinted dog had a litter mate sister dog as a control. At the age of 40 weeks, eight splinted dogs and their controls were first anaesthetised with an intravenous cocktail of pentobarbital (Hankkija, Finland) and water. The dogs were treated in accordance with the principles presented in the National Research Council’s Guide for the Care and Use of Laboratory Animals. The Animal Care and Use Committee of the University of Kuopio approved the design of this experiment.

Synovial fluid samples
Synovial fluid samples were taken by lavage from the splinted, remobilised, and contralateral knee joints, as well as from the knee joints of the control dogs. After the dogs were killed the knee joint was surgically exposed to the level of joint capsule and 3 ml sterile physiological saline was injected through the capsule into the knee joint. The joint was fully extended and flexed 10 times, and thereafter all fluid was collected. The volume of the joint lavage fluid was measured and stored in Eppendorf tubes, at −70°C, until analysed.

Assay of interleukin 1α (IL1α)

The concentration of IL1α in the synovial fluid was determined quantitatively by an immuno-assay with a monoclonal antibody (Immunoenzymometric assay kit, Immunotech s.a., Marseille, France). Samples and standards were incubated in wells of a microtitre plate coated with the first monoclonal antibody, directed against IL1α. After aspiration and washing, a second monoclonal anti-IL1α antibody was added to the wells; this latter antibody was conjugated with acetylcholinesterase. After incubation, the wells were aspirated, rinsed, and the retaining enzymatic activity was determined by the addition of a chromogenic substrate for the acetylcholinesterase. The intensity of the colour is proportional to the IL1α concentration in the samples and standards.

Assay of synovial type phospholipase A2 (PLA2)

The enzyme activity of PLA2, in the synovial fluid was measured with 1-palmitoyl-2-(1-14C)linoneoyl-L-3-phosphatidylethanolamine (lino-PE; 59 mCi/mmol; Amersham, England) as substrate. The standard assay mixture contained 0.1 M Tris-HCl buffer (pH 9.0), 5 mM CaCl2, 0.5 mM sodium deoxycholate, 2.24 µM lino-PE, and 25 µl synovial fluid in a volume of 300 µl. The incubations were carried out for 60 minutes in a water bath at 37°C. The reaction was stopped with 1.25 ml of Dole extraction mixture (2-propanol:n-heptane:0.5 M aqueous sulphuric acid 40:10:1 v/ν). The radioactivity was counted in a liquid scintillation counter (LKB Wallac, Turk, Finland). All results reported are mean values of duplicate analyses.

Measurement of chondroitin sulphate (CS)

Measurement was performed by precipitation of CS with Alcian blue, as described by Björnsson. The specificity for CS was achieved by using low pH (<2.0) in combination with detergent and high salt concentration with 1.0 M guanidine-HCl. Non-sulphated polyanions were excluded by lowering the pH, and hydrophobic interactions of proteins with Alcian blue were minimised by the detergent.

Measurement of hyaluronan (HA)

Synovial fluid HA was measured by an ELISA-like assay using biotinylated HA-binding complexes (bHABC) prepared from the proteoglycan link protein complex of bovine articular cartilage. Briefly, Nunc Covalink tubes (Covalink, Nunc, Roskilde, Denmark) were coated with HA (50 µg/ml, Sigma, St Louis, MO, USA) and blocked with 1% bovine serum albumin (BSA). The samples were first digested with papain (250 µg/ml in 5 mM cysteine, 5 mM EDTA, Sigma) at 60°C for 24 hours and the enzyme was then inactivated by boiling for 10 minutes. The digested samples
and a series of standard HA (5–200 ng/ml) diluted in 6% BSA in phosphate buffered saline (PBS) were mixed with an equal volume of bHABC (450 ng/ml) in small polypropylene tubes (Mekalasi, Kuortane, Finland) and incubated overnight at 4°C. Immediately before the assay the mixtures were incubated for one hour at 37°C. The samples and standards were then transferred to the HA precoated plates, incubated for 90 minutes at 37°C, and washed with 0.5% Tween 20 in PBS. Horseradish peroxidase conjugated streptavidin (1:20 000 in PBS, Vector Laboratories, Burlingame, CA, USA) was added to the plates and left for one hour at 37°C. After washing, the substrate-chromogen solution (O-phenylenediamine dihydrochloride; Sigma, 0.03% H2O2 in 0.1 M citrate buffer, pH 5.0) was added and left for one hour. The reaction was stopped with 8 M H2SO4 and the absorbances were read at 490 nm using a microtitre plate reader (Molecular Devices Corporation, Palo Alto, CA, USA). All results reported are mean values of duplicate analyses.

ASSAYS OF STROMELYSIN (MMP-3) AND TISSUE INHIBITOR OF METALLOPROTEINASES (TIMP)

MMP-3 and TIMP concentrations in synovial fluid were determined by sandwich ELISA, using monoclonal and polyclonal antibodies raised against human recombinant proteins. All assays use a monoclonal antibody against the enzyme or inhibitor as a trapping reagent. For TIMP ELISA, the mouse antihuman TIMP monoclonal antibody, Mac 019, was added to the wells as a trapping reagent, 0.05 mg/well. The second antibody was an IgG fraction of rabbit antihuman TIMP antiserum used at 0.05 mg/well. The assay was developed by incubating the plates with horseradish peroxidase conjugated sheep antirabbit IgG by incubating the plates with horseradish peroxidase conjugated sheep antirabbit IgG enzyme or inhibitor as a trapping reagent. For TIMP, as used in this investigation, detects only free TIMP. The stromelysin assay has a log-linear range of 0.5–100 ng/ml, and the TIMP assay 0.8–30 ng/ml. 

The assay for MMP-3 detects the proforms of the enzyme, the high molecular weight active forms of the enzymes, and the enzymes complexed to TIMP, but not small molecular weight forms or enzymes complexed to α2 macroglobulin. The assay for TIMP, as used in this investigation, detects only free TIMP. The stromelysin assay has a log-linear range of 0.5–100 ng/ml, and the TIMP assay 0.8–30 ng/ml.

SCORING SYNOVITIS BY LIGHT MICROSCOPY

One synovial membrane specimen/dog was taken from the anterolateral joint capsule close to its insertion onto the tibia. The samples were fixed in 4% formaldehyde solution in phosphate buffer (pH 7.0, 0.013 M), embedded in paraffin, sectioned at 5 µm, and stained with haematoxylin and eosin. The sections of synovium were screened by light microscopy, and the greatest number of inflammatory cells (polymorphonuclear leucocytes, lymphocytes, and macrophages) was estimated. Absent inflammation was scored as 0, grade 1 was assigned to slight, and grade 2 to moderate or dense number of inflammatory cells in the samples.

STATISTICAL ANALYSIS

The two tailed non-parametric Wilcoxon’s matched pairs signed ranks test was used for statistical analysis.

Results

RADIOGRAPHS

Radiographs of the knee joints showed no abnormalities in the bony structures or in the width of the joint space in any of the experimental or control dogs.

VOLUME OF SYNOVIAL FLUID

No effusion was seen in the knee joints in any group examined after the dogs were killed. An average of 2.9 (0.2) ml (mean (SD)) joint lavage fluid was collected from the knee joints after injection of 3.0 ml saline. The experimental groups did not differ from each other in this respect.

EFFECT OF IMMobilisation AND REMobilisation ON SYNOVIAL FLUID MEDIATORS

Immobilisation with a splint decreased the concentration of IL1α in synovial fluid to 22% of the control value in dogs with normal weight bearing (p<0.05) (table 1). After the remobilisation period the concentration of IL1α was comparable with the levels seen in contralateral and control joints. Immobilisation, increased weight bearing, or remobilisation did not alter the concentration of MMP-3 or activity of PLA2 (table 1).

After immobilisation the concentration of TIMP-1 was 87% (p<0.05) of the control value, but remobilisation restored it. Increased

<table>
<thead>
<tr>
<th>Marker</th>
<th>Beagles 40 weeks of age</th>
<th>Beagles 90 weeks of age</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Immobilised (n=7)</td>
<td>Contralateral (n=7)</td>
</tr>
<tr>
<td>Interleukin 1α (pg/ml)</td>
<td>0.8 (1.0)*</td>
<td>1.4 (2.6)</td>
</tr>
<tr>
<td>Phospholipase A2 (nmol/min/ml)</td>
<td>21.2 (10.1)</td>
<td>20.9 (5.6)</td>
</tr>
<tr>
<td>MMP-3 (nmol/l)</td>
<td>1.4 (0.3)</td>
<td>1.8 (0.7)</td>
</tr>
<tr>
<td>TIMP-1 (nmol/l)</td>
<td>1.3 (0.5)*</td>
<td>1.9 (1.2)</td>
</tr>
<tr>
<td>MMP-3/TIMP-1</td>
<td>1.3 (0.5)</td>
<td>1.3 (0.5)</td>
</tr>
</tbody>
</table>

Values indicate mean (SD) in each group. The two tailed non-parametric Wilcoxon’s matched pairs signed ranks test was used for statistical analysis.

* p<0.05 compared with controls.
†MMP-3 = matrix metalloproteinase 3; TIMP-1 = tissue inhibitor of metalloproteinases 1.
weight bearing did not induce any statistically significant changes in the concentration of TIMP-1 in the synovial fluid (table 1).

**IMMOBILISATION AND REMOBILISATION EFFECTS ON THE CONCENTRATION OF CS AND HA IN SYNOVIAL FLUID**

The CS concentration was 62% (p<0.05) lower in the synovial fluid lavages of the immobilised joints than in the controls. Remobilisation restored the decreased concentration of CS seen after immobilisation. Increased weight bearing did not alter significantly the concentration of synovial fluid CS. Increased load bearing in the contralateral joint did not alter the concentration of HA (table 2).

**GRADE OF SYNOVITIS**

No synovitis was seen (grade 0) after immobilisation, and synovitis was also absent in control animals and after increased weight bearing. After remobilisation all synovium samples had a normal appearance (grade 0).

**Discussion**

The concentration of markers in the synovial fluid is determined by the rate of their release from cartilage and synovium into the joint cavity relative to the clearance of synovial fluid. The clearance rates of HA, proteoglycans, and large proteoglycan fragments seem to differ from those of water and albumin, as the former substances are partially retained in the joint cavity by the synovial lining. This implies that during muscle contractions, HA, proteoglycans, and their fragments will impact in the intimal matrix and impede the passage of HA, smaller molecular weight compounds, and even water from the joint cavity. The removal of material—for example, blood, from the joint cavity is delayed by immobilisation because the synovial lymph flow depends on joint movements. Thus, in principle, gradual increase of the synovial fluid volume can result from joint immobilisation. However, in this study no increase was recorded in the volume of joint lavage fluids after immobilisation.

Immobilisation of the knee joint in flexion for 11 weeks decreased the concentrations of IL1α, TIMP-1, and CS in the synovial fluid, whereas MMP-3 stayed at the control level or slightly below. The reduced IL1α levels in the synovial fluid suggest that an inflammatory reaction was not active at the time synovial fluid samples were collected. This is in line with the observation that also the levels of PLAy, a marker of inflammation, were not changed. In addition, microscopic examination of the synovium did not disclose any signs of synovitis. These observations are in contrast with those obtained after induction of canine osteoarthritis by tibial valgus osteotomy. After osteotomy, an increase in the concentrations of synovial fluid PLAy, TIMP, and MMP-3 was recorded, and CS showed an upward trend. The assays were the same as used in this study. Microscopic signs of osteoarthritis were also seen. These changes were not present after immobilisation. Thus it is apparent that a more quiescent metabolism is established during the cartilage atrophy that develops after joint immobilisation, manifesting itself also in the composition of the synovial fluid.

The immobilisation-induced decrease of CS in the synovial fluid reflected, most probably, the reduced content of proteoglycans in articular cartilage, and their flux through the synovial fluid after release and partial fragmentation. In an earlier study we showed that after 11 weeks’ joint immobilisation the incorporation of SO4 into the articular cartilage explants was maintained at the control level at the same time as the local concentration of proteoglycans in the cartilage tissue was significantly decreased. This suggests enhanced proteoglycan breakdown instead of reduced synthesis during joint immobilisation. An increase of metalloproteinase levels in the cartilage in comparison with TIMPs would explain the decrease of cartilage proteoglycans after immobilisation. In this study the concentration of TIMP-1 in synovial fluid was reduced by immobilisation, but the molar ratio of MMP-3 and TIMP-1 was not significantly altered (table 1). However, Grumbles et al reported that after four weeks of sling immobilisation there was an increase of proteases and a depression of TIMPs in the disuse atrophy of canine knee cartilages. In rheumatoid human synovial cells IL1α induces the synthesis of metalloproteinases but not of TIMP-1. Inflammatory episodes are part of the natural course of cartilage destruction in rheumatoid arthritis and osteoarthritis. IL1 and tumour necrosis factor α are the key cytokines in arthritis. The possibility cannot be ruled out that IL1α levels of cartilage increased transiently during the first weeks of immobilisation. This would explain the reduction of proteoglycans and cartilage atrophy.

In a series of experiments on canine osteoarthritis by Ratcliffe et al, synovial fluid samples were shown to contain reduced levels of the native chondroitin sulphate epitope (3-B-3), keratan sulphate epitope, sulphated glycosaminoglycan, and link protein. However,
when examined with the same assays, the fluid from joints with disuse atrophy showed increased levels only of keratan sulphate epitope and sulphated glycosaminoglycan.14 Also, these results suggest that the metabolism of proteoglycans in articular cartilage during early osteoarthritis and disuse atrophy are different.15–17

In our study no changes in the concentration of HA in the synovial fluid were seen. Earlier, we found reduced concentrations of both HA and aggrecan in the articular cartilage after immobilisation.18 Because HA comprises only about 2.3–6.3% of total glycosaminoglycans in canine cartilage, and immobilisation causes 16–27% decrease of HA in cartilage,20 it is not surprising that this small change cannot be detected in the synovial fluid, particularly because the synovial fibroblastic cells, and not the chondrocytes, are the main source of HA in synovial fluid.18–19 In sheep, immobilisation of the joint for five months did not significantly reduce the ability of the synovial cells to produce HA.19 Therefore, it is understandable that the level of HA in the synovial fluid and its metabolism in the articular cartilage follow different patterns. CS in the synovial fluid represents proteoglycans or their fragments, or both.22 The decrease in the synovial fluid concentration of CS, and the previously noted reduction of aggrecan in cartilage tissue,22 probably reflect an altered metabolism of aggrecan after joint immobilisation. In contrast with the present immobilisation model, the synthesis and turnover of articular cartilage proteoglycans is increased in the early phase of osteoarthritis,20 and there is a positive correlation between the severity of the disease and the concentration of proteoglycans and/or their fragments in synovial fluid.21

After remobilisation, the activity of PLA, and the concentrations of IL-6, MMP-3, TIMP-1, CS, and HA in synovial fluid did not differ from control values. Evidently, normal joint loading brought the values back to the control level. Neither did the values from the contralateral knee joint, exposed to increased weight bearing during immobilisation, differ from control values, though the concentration of CS showed a (statistically non-significant) upward trend (table 2). This upward trend might reflect an accelerated synthesis and/or release of proteoglycans and/or their fragments from cartilage because we have earlier shown that increased weight bearing can increase the local concentration of glycosaminoglycans in articular cartilage.22

However, we have also noted that the concentration of proteoglycans remains low in certain cartilage locations after the remobilisation period.22 The decreased proteoglycan concentration in articular cartilage was detected in the superficial and intermediate zones on the summit of the medial femoral condyle and in the plateau of the medial condyle of tibia. Those areas represent a small part of the total cartilage area in the bony knee joint, and an even smaller proportion of the total articular cartilage volume. Therefore, a synovial fluid analysis at a single time point 50 weeks after the remobilisation was started, is not likely to disclose focal changes affecting a small proportion of the joint cartilage especially because the associated metabolic events might have occurred much earlier.

The results of this study support the view that reduced joint loading by immobilisation creates an altered equilibrium in cartilage proteoglycan and HA metabolism, which manifests itself also in reduced concentrations of cartilage products in the synovial fluid.18–20 Our earlier results of the effects of joint immobilisation on articular cartilage corroborate this interpretation of reduced matrix turnover.20–22 The alterations seen after joint immobilisation in the markers of synovial fluid are different from those seen in experimental canine osteoarthritis.8–12

This study was supported by grants from the Finnish Cultural Foundation and the Ministry of Education in Finland, the Swedish Medical Research Council, the King Gustaf V 80-year fund, and the Medical Faculty and University Hospital in Lund.

arthritis and osteoarthritis. Its possible role as a proinflamma-
21 Ogston A, Steiner J. The physiological function of
hyaluronidase in synovial fluid: viscoso-elastic and lubri-
22 Haapala J, Lammi MJ, Inkinen R, Parkkinen JJ, Aremen UM,
Arokoski J, et al. Coordinated regulation of hyaluronan and
aggrecan content in the articular cartilage of immobilized
23 Dahl L, Dahl I, Engstrom-Laurent A, Granath K. Concen-
tration and molecular weight of sodium hyaluronate
in synovial fluid from patients with rheumatoid arthritis and
24 Haapala J, Arokoski J, Lammi M, Inkinen R, Parkkinen JJ,
Kiviranta I, et al. Immobilisation causes longstanding
matrix changes both in the immobilised and contralateral
M, Kovenan V, et al. Remobilization does not fully restore
rheumatoid induced articular cartilage atrophy. Clin
26 Björnsson S, Messner K, Gillquist J, Björnsson S, Lohmander LS, et
al. Coordinated regulation of hyaluronan and
aggrecan fragments in human synovial fluid: evidence that
aggrecan mediates cartilage degradation in inflamma-
tory joint disease, joint injury and osteoarthritis. Arthritis
27 Heikkinen LM, Panula HE, Lyyra T, Jurvelin J, Kiviranta
I, et al. Incomplete restoration of immobilization
induced softening of young beagle articular cartilage after
28 Pradelles P, Grassi J, Maclouf J. Enzyme immunoassay of
29 Rönkkö S, Lahtinen R, Vanha-Perttula T. Phospholipases A2
and matrix metalloproteinases (TIMP) and enzyme-inhibi-
30 Wang C, Tammi M, Tammi R. Distribution of HA and its
carbohydrate epitope in synovial fluid: evidence for change
in the HA structure or in the spatial organization of
31 Björnsson S. Simultaneous preparation and quantification
of proteoglycan aggregates from articular cartilage in experi-
mental joint disuse and joint instability. J Orthop Res
32 MacNaul K, Chartrain N, Lark M, Tocci M, Hunsdon N, van den
Berg W. Centrifugal and biochemical comparison of proteolytic
aggregates from articular cartilage in experimental
total joint disuse and joint instability. J Orthop Res
33 MacNaul K, Chartrain N, Lark M, Tocci M, Hunsdon N, van den
Berg W. Centrifugal analysis of synovial fluid aggregate
components in experimental osteoarthritis and joint
34 Walakovits LA, Moore VL, Bhardwaj N, Gallick GS, Lark
MW. Detection of stromelysin and collagenase in synovial
fluid from patients with rheumatoid arthritis and posttrau-
35 Bayne EK, Hutchinson NJ, Walakovits LA, Donatelli S, MacNaul K,
Harper CH, et al. Production, purification and characteriza-
36 Levick JR, Price FM, Mason RM. Synovial matrix-synovial
fluid system of joints. In: Comper WD, ed. Extracellular
77.
37 MacNaul K, Chartrain N, Lark M, Tocci M, Hunsdon N, van den
Berg W. Centrifugal analysis of synovial fluid aggregate
components in experimental osteoarthritis and joint
38 Scott D, Colemen PJ, Mason RM, Levick JR. Gly-
cosaminoglycan depletion greatly raises the hydraulic
permeability of rabbit joint synovial lining. Exp Physiol
1997;82:603–6.
39 Edwards J. Synovial physiology in the context of
osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, et
eds. Osteoarthritis. Oxford: Oxford University Press,
40 Lohmander LS, Neame P, Sandy J. The structure of aggre-
can fragments in human synovial fluid: evidence that
aggrecan mediates cartilage degradation in inflamma-
tory joint disease, joint injury and osteoarthritis. Arthritis
41 Messner K, Gilgque J, Björnsson S, Lohmander LS. Proteo-
glycans in rabbit joint fluid correlated to arthrosis.
42 MacNaul K, Chartrain N, Lark M, Tocci M, Hunsdon N, van den
Berg W. Centrifugal analysis of synovial fluid aggregate
components in experimental osteoarthritis and joint
43 MacNaul K, Chartrain N, Lark M, Tocci M, Hunsdon N, van den
Berg W. Centrifugal analysis of synovial fluid aggregate
components in experimental osteoarthritis and joint
44 van den Berg W. Centrifugal analysis of synovial fluid aggregate
components in experimental osteoarthritis and joint
45 MacNaul K, Chartrain N, Lark M, Tocci M, Hunsdon N, van den
Berg W. Centrifugal analysis of synovial fluid aggregate
components in experimental osteoarthritis and joint
46 MacNaul K, Chartrain N, Lark M, Tocci M, Hunsdon N, van den
Berg W. Centrifugal analysis of synovial fluid aggregate
components in experimental osteoarthritis and joint
47 MacNaul K, Chartrain N, Lark M, Tocci M, Hunsdon N, van den
Berg W. Centrifugal analysis of synovial fluid aggregate
components in experimental osteoarthritis and joint
48 MacNaul K, Chartrain N, Lark M, Tocci M, Hunsdon N, van den
Berg W. Centrifugal analysis of synovial fluid aggregate
components in experimental osteoarthritis and joint
49 Sandy JD, Adams ME, Billingham MEJ, Plaas A, Muir H. In-
vivo and in-vitro stimulation of chondrocyte biosyn-
thetic activity in early experimental osteoarthritis.
50 Sandy JD, Adams ME, Billingham ME, Plaas A, Muir H. In-
vivo and in-vitro stimulation of chondrocyte biosyn-
thetic activity in early experimental osteoarthritis.
51 Sandy JD, Adams ME, Billingham MEJ, Plaas A, Muir H. In-
vivo and in-vitro stimulation of chondrocyte biosyn-
thetic activity in early experimental osteoarthritis.
52 Sandy JD, Adams ME, Billingham MEJ, Plaas A, Muir H. In-
vivo and in-vitro stimulation of chondrocyte biosyn-
thetic activity in early experimental osteoarthritis.
53 Sandy JD, Adams ME, Billingham MEJ, Plaas A, Muir H. In-
vivo and in-vitro stimulation of chondrocyte biosyn-
thetic activity in early experimental osteoarthritis.
54 Sandy JD, Adams ME, Billingham MEJ, Plaas A, Muir H. In-
vivo and in-vitro stimulation of chondrocyte biosyn-
thetic activity in early experimental osteoarthritis.
55 Sandy JD, Adams ME, Billingham MEJ, Plaas A, Muir H. In-
vivo and in-vitro stimulation of chondrocyte biosyn-
thetic activity in early experimental osteoarthritis.
Decline after immobilisation and recovery after remobilisation of synovial fluid IL1, TIMP, and chondroitin sulphate levels in young beagle dogs

J Haapala, J P A Arokoski, S Rönkkö, U Ågren, V-M Kosma, L S Lohmander, M Tammi, H J Helminen and I Kiviranta

Ann Rheum Dis 2001 60: 55-60
doi: 10.1136/ard.60.1.55

Updated information and services can be found at:
http://ard.bmj.com/content/60/1/55

These include:

References
This article cites 46 articles, 8 of which you can access for free at:
http://ard.bmj.com/content/60/1/55#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Degenerative joint disease (4641)
Musculoskeletal syndromes (4951)
Immunology (including allergy) (5144)
Clinical diagnostic tests (1282)
Osteoarthritis (931)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/